Matinas BioPharma

170 articles about Matinas BioPharma

• Matinas BioPharma Prices $10 Million Registered Direct Offering

  4/3/2024

  Matinas BioPharma Holdings, Inc. announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering.

• Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

  3/22/2024

  Matinas BioPharma Holdings, Inc. announced that on March 21, 2024, the Company received written notification from the NYSE American LLC stating that the Company has regained compliance with the NYSE American’s continued listing standards.

• Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

  2/26/2024

  Matinas BioPharma provided an update from its ongoing Compassionate/Expanded Use Access Program with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

• Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

  2/20/2024

  Matinas BioPharma (NYSE American: MTNB) announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited treatment options (the “ORALTO” trial).

• Matinas BioPharma to Present at Biotech Showcase 2024

  1/3/2024

  Matinas BioPharma announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the Biotech Showcase 2024 on Tuesday, January 9, 2024 at 11:00 a.m. Pacific time.

• Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

  12/27/2023

  Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

• Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

  12/21/2023

  Matinas BioPharma Holdings, Inc. announces receipt of written feedback from U.S. Food and Drug Administration (FDA) on its proposed revised protocol for a Phase 3 study of MAT2203 in patients with invasive aspergillosis with limited or no treatment options.

• Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

  11/8/2023

  Matinas BioPharma reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

• Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

  11/7/2023

  Matinas BioPharma Holdings, Inc. announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors.

• Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023

  11/1/2023

  Matinas BioPharma Holdings, Inc. announces that it will report third quarter 2023 financial results after market close on Wednesday, November 8, 2023.

• Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

  10/11/2023

  Matinas BioPharma announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B.

• Matinas BioPharma to Present at Two Investment Conferences in October 2023

  9/28/2023

  Matinas BioPharma announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences.

• Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

  9/22/2023

  Matinas BioPharma announced that it has received a deficiency letter from NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.

• Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

  8/22/2023

  Matinas BioPharma announces that University of Minnesota Medical School researchers published results from the Phase 2 EnACT trial evaluating MAT2203 for the treatment of cryptococcal meningitis as a Major Article and Editor’s Choice in Clinical Infectious Diseases.

• Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

  8/9/2023

  Matinas BioPharma, a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

• Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

  8/2/2023

  Matinas BioPharma Holdings, Inc. announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the BTIG Virtual Biotechnology Conference 2023 being held August 7-8, 2023.

• Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

  7/26/2023

  Matinas BioPharma Holdings, Inc. announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023.

• Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

  5/11/2023

  Matinas BioPharma (NYSE American: MTNB) announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time.

• Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

  5/10/2023

  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ended March 31, 2023 and provides a business update.

• Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

  4/18/2023

  Matinas BioPharma announces that Marisa H. Miceli, MD, Professor of Medicine, at the University of Michigan and her team delivered an oral presentation earlier at the 33rd ECCMID in Copenhagen discussing MAT2203’s clinical impact in treating a compassionate use patient suffering from Rhodotorula mucilaginosa, a rare and opportunistic invasive fungal infection.